Elizabeth A. Mittendorf, MD, PhD
Recent immunotherapy trials have produced mixed results in patients with breast cancer. A pair of trials that used checkpoint inhibitors as monotherapy reported lackluster overall response rates (ORRs). Trials that paired immunotherapy with chemotherapy, on the other hand, fared better, and there are promising hints that immunotherapies combined with some targeted agents might also work better than immunotherapy alone.
... to read the full story